Friday, November 23, 2012 - The Pradaxa internal bleeding lawyers at The Onder Law Firm are currently providing free consultations to persons, or their families, suffering from internal bleeding or stroke after using the pharmaceutical Pradaxa. Pradaxa, an anticoagulant, was approved by the FDA in 2010 to prevent stroke in people with atrial fibrillation (AFib). Pradaxa was the first drug approved by the FDA to treat AFib since the 1950‘s. Boehringer Ingelheim, the manufacturer of Pradaxa, marketed the drug as a safer alternative to warfarin; however, the company admitted to hundreds of internal bleeding deaths having occurred from March of 2008 to October of 2011, causing the FDA to start an investigation into Pradaxa internal bleeding dangers in December of 2011 (forbes.com/sites/larryhusten/2011/12/07/fda-undertakes-safety-review-of-dabigatran-pradaxa/). The FDA required additional labeling on Pradaxa packaging warning of internal bleeding risk in January of 2012.
Pradaxa internal bleeding lawsuits were filed, leading to the Pradaxa Products Liability Litigation (United States District Court, Southern District of Illinois, MDL no. 2385), which also includes claims for hemorrhagic stroke. The Onder Law Firm, which handles medical device and pharmaceutical products liability cases nationwide, partner Mark Niemeyer was selected as Co-Liaison Counsel for the Pradaxa lawsuit on September 27, 2012.
The Onder Law Firm‘s pharmaceutical division Pradaxa internal bleeding lawyers are offering a free case review with no further obligation to the families of persons who experienced severe internal bleeding while taking Pradaxa. All Pradaxa claims are being handled on a contingency basis with no cost to the client unless they successfully win compensation for them.
Additionally, The Onder Law Firm invites other law firms to consult on Pradaxa internal bleeding lawsuits, and is available either to handle their cases or work as co-counsel.